Recently approved direct-acting antiviral (DAA) regimens can safely and effectively treat hepatitis C without interferon, with cure rates often exceeding 95%, according to a recently published review.

“Oral DAA regimens that are highly efficacious, well-tolerated, and relatively short in duration are now available for all [hepatitis C virus] genotypes and for patient populations historically considered difficult to cure,” wrote Oluwaseun Falade-Nwulia, MBBS, MPH, from Johns Hopkins School of Medicine in Baltimore and co-authors.

The systematic review, which looked at 42 studies of DAAs used in interferon-free regimens, is published online in the Annals of Internal Medicine.

Read the review article, and crtique, in MedPage Today here.